 |
TODAY's HIGHLIGHTS, February 24
Available on the WCN'22 Platform
|
|
Pre-congress Courses
|
|
*Pre-Congress
Courses are subject to an additional registration fee.
|
|
|
|
First-rate opportunities to refresh old skills, learn new ones, and meet fellow kidney
professionals at courses presented by world-class leaders.
|
|
|
|
Interventional Nephrology:
A review of new developments in the pathophysiology and treatment of
hyponatremia, and potassium and acid-base disorders.
|
|
|
Renal Pathology:
Provides an in-depth update on commonly encountered kidney lesions and the
potential utility of ancillary techniques. Plus, recent insights into the
pathophysiologic aspects of diseases and recommendations for further molecular
and genetic studies will also be addressed.
|
|
|
|
 Advocacy and Policy - New Skills for the Modern
Nephrologist:
Shares the principles and practicalities of designing and conducting effective
advocacy campaigns.
|
|
|
|
Acid-Base and Electrolytes - A Chance to Revisit:
A review of new developments in the pathophysiology and treatment of
hyponatremia, and potassium and acid-base disorders.
|
|
|
|
Epidemiology:
An overview of the most salient approaches used in clinical nephrology research
today.
|
|
|
|
Nephrology Annual Review:
Three sessions on current issues in nephrology: advances in glomerulonephritis
therapy, lessons learned from COVID-19, and an overview of chronic kidney
disease/failure.
|
|
|
|
Nursing, Nutrition, and Allied
Health Professionals Symposium:
Focuses on integrated, interprofessional care models - the ideal paradigm for all
kidney health professionals and patient partners.
|
|
|
|
|
|
|
|
|
Special session: Declaration of Istanbul (DICG)
The Declaration of Istanbul Custodian Group (DICG) presents its important work on
raising awareness on transplant issues, notably the transplantation of foreign
nationals in North America, the meaning of financial neutrality for living donors, and
the global organ trafficking registry project.
|
|
|
|
|
|
|
|
The ISN Warmly Thanks 2022 Outgoing Leaders: Visit the Leadership Gallery
|
The ISN recognizes and wholeheartedly thanks several key leaders whose terms in various
leadership groups ended following the General Assembly yesterday.
We invite you to visit the 2022 Outgoing Leaders Gallery to acknowledge these
enthusiastic and committed ISN members.
|
|
|
|
We sincerely thank all the outgoing ISN leaders. Their dedication and tireless efforts
continually drive forward the ISN’s mission of equitable access to sustainable kidney
health for all.
|
|
|
|
|
|
|
|
|
|
SPONSORED CONTENT: Join Travere’s Industry Symposium
Saturday, February 26 at 23:00 - 00:00 MYT |
|
|
|
|
The Link Between Endothelin-1, Angiotensin II, and Proteinuria in the Pathophysiology of CKD
|
|
You are invited to join Travere’s industry symposium on Saturday, February 26 at 23:00–00:00 MYT
(16:00–17:00 CET, 10:00–11:00 ET) to hear from our experts, Prof. Jonathan Barratt (UK), Dr. Donald
Kohan (USA), and Dr. Ariela Benigni (Italy), on how endothelin-1 (ET-1) and angiotensin II (Ang II)
act in tandem to play fundamental roles in the pathophysiology and progression of CKD in several
glomerular diseases, including focal segmental glomerulosclerosis (FSGS) and immunoglobulin A (IgA)
nephropathy, and how elevated proteinuria is strongly associated with progressive kidney disease.(1,2)
|
|
In his talk at WCN’22, Dr. Kohan will discuss how ET-1 is widely produced throughout the kidney and
how ET-1 and Ang II act in tandem via multiple mechanisms to affect a range of renal compartments
and cell types.(2) He will go on to look at the pathophysiological setting of CKD, where
ET-1 and Ang II amplify glomerular and tubular damage and contribute to the development of an
inflammatory environment, worsening proteinuria and a progressive decline in kidney function.(2-4)
|
|
Next, Dr. Benigni will focus on the role of ET-1 and Ang II specifically in FSGS and IgA
nephropathy. In IgA nephropathy, ET-1 and Ang II have been implicated
in amplifying several pathophysiological processes, including
mesangial cell proliferation, extracellular matrix production, podocyte cytoskeletal alterations,
and
amplification of tubulointerstitial fibrosis and inflammation.(1-4) In FSGS, ET-1 and
Ang II act in tandem to amplify ongoing podocyte injury, including nephrin shedding,
foot process effacement, podocyte depletion and apoptosis, and dysfunction and loss of endothelial
cells and the associated glycocalyx.(5-10) These processes result in increased
proteinuria, which drives further tubular
interstitial inflammation and fibrosis, alongside induction of multiple pathogenic processes,
culminating in a progressive decline in kidney function.(11-14)
|
|
Prof. Barratt will then focus on the clinical significance of proteinuria. In IgA nephropathy,
proteinuria is the single strongest and modifiable prognostic indicator for disease progression.(15,16)
Patients with
proteinuria >0.75-1 g/24 hrs (despite
at least 90 days of maximized renin-angiotensin system blockade) are defined by the KDIGO
guidelines as those at high risk of progression to kidney failure.(17) Furthermore, each
incremental gram per day above 1 g/24 hrs of proteinuria is associated with a 10- to 25-fold more
rapid rate of decline in kidney function.(15) In FSGS, the goal of therapy is to achieve
complete remission of proteinuria (KDIGO guidelines: urine protein:creatinine [UP/C] of <0.3
g/24 hrs and stable serum creatinine), thereby slowing progressive kidney disease(17,18)
and alleviating symptoms to improve patient quality of life.(19) Additionally, in FSGS,
proteinuria is predictive of a poor prognosis, and a biomarker of disease severity.(20)
|
|
A considerable unmet clinical need remains for the treatment of both FSGS and IgA nephropathy. A
substantial number of patients receiving guideline recommended therapies remain above target
proteinuria levels,(21,22) requiring long periods of therapy to achieve remission,
risking
significant
toxicity.(17,20) In his talk at WCN’22, Prof. Barratt will also consider investigational
agents in development for the treatment of IgA nephropathy and FSGS.
|
|
Questions can be submitted throughout the symposium for our panel to answer and discuss in the
breakout Q&A session directly after. We look forward to welcoming you for what promises to be an
interesting and lively discussion.
|
References:
- Siragy H & Carey R. Am J Nephrol 2010; 31:541–550
- Komers R
& Plotkin H. Am J Physiol Regul Integr Comp
Physiol 2016; 310:R877‒R884
- Kohan
DE & Barton M. Kidney Int 2014; 86:896–904
- Raina R, et al. Kidney Dis (Basel) 2020; 6:22–34
- Kohan DE, et
al. Compr Physiol 2011; 1:883–919
- Vignon-Zellweger N, et
al. Life Sci 2012;
91:490–500
- Kandasamy
Y, et
al. Biomark Res 2014; 2:21–28
- Barton M & Tharaux P-L.
Clin
Kidney J 2012; 5:17–27
- Barton M & Sorokin A. Semin Nephrol 2015; 35:156–167
- Morigi M, et al. Am J Pathol 2005; 166:1309–1320
- Reuggenenti P, et al. Kidney Int 1998; 53:1209–1216
- Wyatt RJ & Julian BA. N Engl J
Med 2013; 368:2402–2414
- Abbate M, et al. J Am Soc Nephrol 2006; 17:2974–2984
- Sharma S & Smyth B. Kidney
Blood Press Res 2021; 46:411−420
- Reich HN, et
al. J Am Soc Nephrol 2007; 18:3177–3183
- Inker LA, et
al. Am J Kidney Dis 2016; 68:392–401
- Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021
Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney International
2021; 100(4S):S1–S276.
- Troyonov S,
et al. J Am Soc Nephrol 2005; 16:1061–1068
- Mathias SD, et
al. Am J Kidney Dis 2017; 70:532–540
- Korbet SM. J
Am Soc Nephrol 2012;
23:1769–1776
- Woo KT, et al. Kidney Int 2000; 58:2485–2491
- Coppo R, et al. J Am Soc Nephrol 2007; 18:1880–1888
|
|
|
 |
What’s in store: February 25, 2022
|
|
|
Join us again tomorrow for the opening ceremony and
another full day of activities!
|
|
Sessions
include:
|
 |
Friday February 25, 2022, 18:00 - 19:30 MYT, Room 2 (Virtual)
(convert to your time zone here)
|
|
|
Friday, February 25, 21:30 - 22:30 MYT, Room 3 (Virtual)
(convert to your time zone here)
|
|
|
Friday, February 25, 21:30 - 22:30 MYT, Room 4 (Virtual)
(convert to your time zone here)
|
|
|
Friday, February 25, 17:30 - 18:00 MYT, Topical Networking
(convert to your time zone here)
|
|
|
|
|
Whatever your speciality, level of experience, or location, there is a pre-congress course or
session for you at WCN’22. We look forward to seeing you there and hearing from you during
the live sessions.
|
|
|
|
|
|
We want to hear from you! Share your experience of WCN'22 and post your pictures and messages
on social platforms: Twitter, Instagram, Facebook, and LinkedIn. Use hashtag #ISNWCN
to get your posts featured on the WCN’22 Social Media Wall.
View this year's abstracts. These have also been published in the WCN’22 Kidney
International Reports supplement.
